tiprankstipranks
Mainz Biomed Secures $8 Million in Follow-On Offering
Company Announcements

Mainz Biomed Secures $8 Million in Follow-On Offering

Story Highlights

Pick the best stocks and maximize your portfolio:

Mainz Biomed B.V. ( (MYNZ) ) has provided an announcement.

Mainz Biomed has successfully closed an $8 million follow-on offering, selling 1,367,521 units at $5.85 per unit. This financial boost is expected to support the company’s efforts in advancing their diagnostic products, potentially enhancing their position in the molecular genetics diagnostics industry.

More about Mainz Biomed B.V.

Mainz Biomed is a molecular genetics diagnostic company that specializes in developing market-ready diagnostic solutions for life-threatening conditions. Their flagship product is ColoAlert, a non-invasive early-detection test for colorectal cancer marketed in Europe. The company is also conducting an FDA clinical study for US approval and has a product candidate called PancAlert for pancreatic cancer screening.

YTD Price Performance: -88.45%

Average Trading Volume: 103,960

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $10.73M

For detailed information about MYNZ stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyMainz Biomed NV trading resumes
TheFlyMainz Biomed NV trading halted, volatility trading pause
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App